A Georgia woman has filed a new Invokana lawsuit that purports she nearly died as a result of ketoacidosis complications allegedly related to her use of the Type 2 diabetes medication. The complaint, which was filed late last month in the U.S. District Court, Northern District of Georgia, claims that Invokana is an “unreasonably dangerous” medication that may cause patients to suffer abnormally high and potentially dangerous blood acid levels.
Invokana was launched in March 2013 by Johnson & Johnson’s Janssen Pharmaceuticals unit, and was the first SGLT2 inhibitor medication approved in the U.S. for the treatment of Type 2 diabetes. According to this recent filing, the plaintiff was prescribed Invokana on October 21, 2013 to control her Type 2 diabetes. Just two weeks later, she was admitted to the hospital after experiencing significant weight loss, nausea and repeated vomiting, The plaintiff was diagnosed with diabetic ketoacidosis on November 3, 2013, which she says nearly resulted in her death and left her with long-term injuries.
“Invokana is unreasonably dangerous and defective as formulated, putting consumers, including Plaintiff, at an unreasonable risk of suffering injury and death,” the lawsuit states. “As the developers, manufacturers and distributors of Invokana, Defendants knew or should have known that it was associated with serious complications, including diabetic ketoacidosis.”
Diabetic ketoacidosis occurs when toxic acids called ketones build up in the blood. It is common in Type 1 diabetics, but rarely presents in people with Type 2, such as the plaintiff in this case. Symptoms associated with the disorder include difficulty breathing, nausea, vomiting, abdominal pain, confusion, fatigue or sleepiness.
In May, the U.S. Food & Drug Administration (FDA) disclosed that it was investigating 20 reports of ketoacidosis in patients taking SGLT2 inhibitors, most of whom were using the drugs to control Type 2 diabetes. All of the cases resulted in emergency treatment or hospitalization. The FDA’s review is ongoing, as it works to determine whether or not this potential complication should be noted on the labeling for Invokana and other SGLT2 inhibitors.
Bernstein Liebhard LLP is currently reviewing potential Invokana lawsuit and other legal claims involving SGLT2 inhibitors and diabetic ketoacidosis. If you would like to learn more, please contact our office at .